Multitumor Case Series of Germline BRCA1 , BRCA2 and CHEK2 -Mutated Patients Responding Favorably on Immune Checkpoint Inhibitors.

MLA

Kinget, Lisa, et al. “Multitumor Case Series of Germline BRCA1 , BRCA2 and CHEK2 -Mutated Patients Responding Favorably on Immune Checkpoint Inhibitors.” Current Oncology (Toronto, Ont.), vol. 28, no. 5, Aug. 2021, pp. 3227–39. EBSCOhost, https://doi.org/10.3390/curroncol28050280.

APA

Kinget, L., Bechter, O., Punie, K., Debruyne, P. R., Brems, H., Clement, P., Roussel, E., Van Herck, Y., Albersen, M., Baldewijns, M., Schöffski, P., & Beuselinck, B. (2021). Multitumor Case Series of Germline BRCA1 , BRCA2 and CHEK2 -Mutated Patients Responding Favorably on Immune Checkpoint Inhibitors. Current Oncology (Toronto, Ont.), 28(5), 3227–3239. https://doi.org/10.3390/curroncol28050280

Chicago

Kinget, Lisa, Oliver Bechter, Kevin Punie, Philip R Debruyne, Hilde Brems, Paul Clement, Eduard Roussel, et al. 2021. “Multitumor Case Series of Germline BRCA1 , BRCA2 and CHEK2 -Mutated Patients Responding Favorably on Immune Checkpoint Inhibitors.” Current Oncology (Toronto, Ont.) 28 (5): 3227–39. doi:10.3390/curroncol28050280.